Recombinant Full Length Human AQP2 Protein, GST-tagged

• Cat.No.: AQP2-1156HF
• Product Overview: Human AQP2 full-length ORF ( NP_000477.1, 1 a.a. - 271 a.a.) recombinant protein with GST-tag at N-terminal.

Specification

• Description: This gene encodes a water channel protein located in the kidney collecting tubule. It belongs to the MIP/aquaporin family, some members of which are clustered together on chromosome 12q13. Mutations in this gene have been linked to autosomal dominant and recessive forms of nephrogenic diabetes insipidus. [provided by RefSeq, Oct 2008]
• Source: In Vitro Cell Free System
• Species: Human
• Tag: GST
• Molecular Mass: 55.2 kDa
• Protein Length: 271 amino acids
• AA Sequence: MWELRSIAFS RAVFAEFLAT LLFVFFGLGS ALNWPQALPS VLQIAMAFGL GIGTLVQALG HISGAHINPA VTVACLVGCH VSVLRAAFYV AAQLLGAVAG AALLHEITPA DIRGDLAVNA LSNSTTAGQA VTVELFLTLQ LVLCIFASTD ERRGENPGTP ALSIGFSVAL GHLLGIHYTG CSMNPARSLA PAVVTGKFDD HWVFWIGPLV GAILGSLLYN YVLFPPAKSL SERLAVLKGL EPDTDWEERE VRRRQSVELH SPQSLPRGTK A
• Applications: Enzyme-linked Immunoabsorbent Assay; Western Blot (Recombinant protein); Antibody Production; Protein Array
• Storage: Store at -80 centigrade. Aliquot to avoid repeated freezing and thawing.
• Storage Buffer: 50 mM Tris-HCl, 10 mM reduced Glutathione, pH=8.0 in the elution buffer.

Gene Information

• Gene Name: AQP2 aquaporin 2 (collecting duct) [ Homo sapiens ]
• Official Symbol: AQP2
• Synonyms: AQP2; aquaporin 2 (collecting duct); aquaporin-2; AQP-2; aquaporin-CD; ADH water channel; water-channel aquaporin 2; collecting duct water channel protein; water channel protein for renal collecting duct; AQP-CD; WCH-CD; MGC34501
• Gene ID: 359
• mRNA Refseq: NM_000486
• Protein Refseq: NP_000477
• MIM: 107777
• UniProt ID: P41181

Reviews

04/15/2023

This can be particularly important in clinical trials to ensure accurate and reliable results.

11/05/2021

Their prompt assistance and guidance contribute to enhancing the success and efficiency of my work with the AQP2 protein.

04/21/2021

Manufacturers may provide documentation of the protein's validation, which includes information about its purity, concentration, stability, and potential contaminants.

02/02/2017

They can assist in identifying the most suitable experimental protocols or provide recommendations for optimal usage.

01/23/2016

Manufacturers can provide researchers with purified and validated AQP2 protein, ensuring its quality and reliability for use in experiments and trials.

Q&As

Can AQP2-related disorders be inherited?

Yes, AQP2-related disorders can be inherited. Some forms of nephrogenic diabetes insipidus (NDI) are caused by genetic mutations in the AQP2 gene, which can be inherited from one or both parents. These genetic mutations result in impaired or absent functional AQP2 channels, leading to the development of NDI.

Can AQP2-related disorders be inherited?

Yes, AQP2-related disorders can be inherited. Some forms of nephrogenic diabetes insipidus (NDI) are caused by genetic mutations in the AQP2 gene, which can be inherited from one or both parents. These genetic mutations result in impaired or absent functional AQP2 channels, leading to the development of NDI.

Can AQP2-related disorders affect individuals of any age?

Yes, AQP2-related disorders can affect individuals of any age. Some forms of AQP2 dysfunction, like congenital nephrogenic diabetes insipidus (NDI), may be present from birth and can affect infants and young children. On the other hand, acquired forms of NDI can develop later in life due to factors such as medication side effects, genetic mutations, kidney damage, or other medical conditions. It is important to consider the potential presence of AQP2-related disorders in individuals of all ages who present with symptoms such as excessive thirst, frequent urination, and electrolyte imbalances.

Can AQP2-related disorders affect individuals of any age?

Yes, AQP2-related disorders can affect individuals of any age. Some forms of AQP2 dysfunction, like congenital nephrogenic diabetes insipidus (NDI), may be present from birth and can affect infants and young children. On the other hand, acquired forms of NDI can develop later in life due to factors such as medication side effects, genetic mutations, kidney damage, or other medical conditions. It is important to consider the potential presence of AQP2-related disorders in individuals of all ages who present with symptoms such as excessive thirst, frequent urination, and electrolyte imbalances.

Is there any known post-translational modification of AQP2?

Yes, AQP2 undergoes several post-translational modifications, including phosphorylation and ubiquitination. Phosphorylation plays a critical role in the intracellular trafficking and translocation of AQP2 to the cell membrane, while ubiquitination is involved in the degradation of AQP2.

Can lifestyle modifications be helpful in managing AQP2-related disorders?

Yes, lifestyle modifications can be helpful in managing AQP2-related disorders, especially in conditions like nephrogenic diabetes insipidus (NDI). These modifications may include ensuring adequate fluid intake to prevent dehydration, dietary adjustments to maintain electrolyte balance, and avoiding excessive alcohol and caffeine consumption, which can increase urine production. It is always important to consult with a healthcare professional for personalized recommendations based on the specific condition and individual needs.

Can lifestyle modifications be helpful in managing AQP2-related disorders?

Yes, lifestyle modifications can be helpful in managing AQP2-related disorders, especially in conditions like nephrogenic diabetes insipidus (NDI). These modifications may include ensuring adequate fluid intake to prevent dehydration, dietary adjustments to maintain electrolyte balance, and avoiding excessive alcohol and caffeine consumption, which can increase urine production. It is always important to consult with a healthcare professional for personalized recommendations based on the specific condition and individual needs.

What specific electrolyte imbalances can occur due to AQP2 dysfunction?

AQP2 dysfunction can result in an imbalance of electrolytes such as sodium and potassium. In conditions like nephrogenic diabetes insipidus (NDI), where AQP2 is impaired, there is impaired water reabsorption and excessive urinary output. This can lead to dehydration and subsequent electrolyte imbalances, including hyponatremia (low sodium levels) and hyperkalemia (high potassium levels).

What specific electrolyte imbalances can occur due to AQP2 dysfunction?

AQP2 dysfunction can result in an imbalance of electrolytes such as sodium and potassium. In conditions like nephrogenic diabetes insipidus (NDI), where AQP2 is impaired, there is impaired water reabsorption and excessive urinary output. This can lead to dehydration and subsequent electrolyte imbalances, including hyponatremia (low sodium levels) and hyperkalemia (high potassium levels).

What are the potential complications or long-term effects of AQP2-related disorders?

The potential complications and long-term effects of AQP2-related disorders can vary depending on the specific condition and its severity. In conditions like nephrogenic diabetes insipidus (NDI), if left untreated or poorly managed, there is an increased risk of dehydration, electrolyte imbalances, and kidney damage. These complications can lead to symptoms such as fatigue, muscle weakness, dizziness, and in severe cases, kidney failure. It is important for individuals with AQP2-related disorders to receive proper medical care and ongoing management to prevent and address these potential complications.

What are the potential complications or long-term effects of AQP2-related disorders?

The potential complications and long-term effects of AQP2-related disorders can vary depending on the specific condition and its severity. In conditions like nephrogenic diabetes insipidus (NDI), if left untreated or poorly managed, there is an increased risk of dehydration, electrolyte imbalances, and kidney damage. These complications can lead to symptoms such as fatigue, muscle weakness, dizziness, and in severe cases, kidney failure. It is important for individuals with AQP2-related disorders to receive proper medical care and ongoing management to prevent and address these potential complications.

How is AQP2 involved in the urine concentrating mechanism?

AQP2 plays a vital role in the urine concentrating mechanism in the kidneys. When vasopressin is released, AQP2 translocates from intracellular vesicles to the apical membrane of collecting duct cells. This process increases the permeability of water, allowing it to be reabsorbed from the urine back into the bloodstream, concentrating the urine.

How is AQP2 involved in the urine concentrating mechanism?

AQP2 plays a vital role in the urine concentrating mechanism in the kidneys. When vasopressin is released, AQP2 translocates from intracellular vesicles to the apical membrane of collecting duct cells. This process increases the permeability of water, allowing it to be reabsorbed from the urine back into the bloodstream, concentrating the urine.

What are some disorders or diseases associated with AQP2 dysfunction?

Mutations or dysregulation of AQP2 can lead to several disorders related to water balance, including nephrogenic diabetes insipidus (NDI). This condition impairs the kidney's ability to concentrate urine, resulting in excessive thirst and urination.

Are there any ongoing research studies or advancements in understanding AQP2-related disorders?

Yes, research on AQP2-related disorders is ongoing. Scientists are studying various aspects such as the molecular mechanisms behind AQP2 regulation, the development of targeted therapies for AQP2 dysfunction, and the identification of genetic mutations associated with these disorders. Furthermore, advancements in genetic testing techniques have allowed for better diagnosis and classification of AQP2-related disorders, leading to improved patient management and personalized treatment approaches.

Are there any ongoing research studies or advancements in understanding AQP2-related disorders?

Yes, research on AQP2-related disorders is ongoing. Scientists are studying various aspects such as the molecular mechanisms behind AQP2 regulation, the development of targeted therapies for AQP2 dysfunction, and the identification of genetic mutations associated with these disorders. Furthermore, advancements in genetic testing techniques have allowed for better diagnosis and classification of AQP2-related disorders, leading to improved patient management and personalized treatment approaches.

Can genetic mutations in the AQP2 gene lead to water imbalance disorders?

Yes, mutations in the AQP2 gene can cause hereditary nephrogenic diabetes insipidus (NDI), a condition characterized by the inability of the kidneys to concentrate urine. These mutations can affect AQP2 synthesis, trafficking, or function, leading to decreased water reabsorption and excessive urination.

Can AQP2-related disorders be cured?

Currently, there is no known cure for AQP2-related disorders. However, effective management and treatment approaches can significantly improve the quality of life for individuals with these conditions. Depending on the specific disorder, treatments may include medication, dietary modifications, fluid management, and addressing any underlying causes or contributing factors. Ongoing research aims to develop more targeted therapies and interventions to better manage and potentially reverse AQP2 dysfunction, but as of now, the focus is on symptom management and preventing complications.

Can AQP2-related disorders be cured?

Currently, there is no known cure for AQP2-related disorders. However, effective management and treatment approaches can significantly improve the quality of life for individuals with these conditions. Depending on the specific disorder, treatments may include medication, dietary modifications, fluid management, and addressing any underlying causes or contributing factors. Ongoing research aims to develop more targeted therapies and interventions to better manage and potentially reverse AQP2 dysfunction, but as of now, the focus is on symptom management and preventing complications.

Are there any physiological conditions that can affect AQP2 expression?

Several physiological conditions can affect AQP2 expression. For example, dehydration stimulates the release of vasopressin, leading to increased AQP2 expression and water reabsorption. On the other hand, excessive water intake or the use of certain medications, such as diuretics, can suppress AQP2 expression, resulting in increased urine output.

Can AQP2 be targeted for therapeutic purposes?

Targeting AQP2 could potentially be useful in the treatment of certain water balance disorders. For instance, pharmacological agents that enhance AQP2 expression or function may be beneficial in patients with nephrogenic diabetes insipidus. However, further research is needed to develop specific and safe therapeutic strategies.

How does AQP2 differ from other aquaporin proteins?

AQP2 is a specific member of the aquaporin family, characterized by its expression primarily in the kidney and involvement in water reabsorption. It differs from other aquaporin proteins in terms of its tissue distribution, regulation, and function.

Are there any treatments or therapies available for AQP2-related disorders?

The treatment options for AQP2-related disorders depend on the specific condition. In nephrogenic diabetes insipidus (NDI), medication options may include thiazide diuretics, which reduce urine production, or nonsteroidal anti-inflammatory drugs (NSAIDs) that can increase the responsiveness of the kidneys to vasopressin. In some cases, dietary adjustments and fluid management are also prescribed. However, the specific treatment plan will be determined by a healthcare professional and tailored to the individual patient's needs.

Are there any treatments or therapies available for AQP2-related disorders?

The treatment options for AQP2-related disorders depend on the specific condition. In nephrogenic diabetes insipidus (NDI), medication options may include thiazide diuretics, which reduce urine production, or nonsteroidal anti-inflammatory drugs (NSAIDs) that can increase the responsiveness of the kidneys to vasopressin. In some cases, dietary adjustments and fluid management are also prescribed. However, the specific treatment plan will be determined by a healthcare professional and tailored to the individual patient's needs.

Are there any natural or synthetic compounds that modulate AQP2 expression or function?

Certain compounds, such as synthetic vasopressin analogs (vasopressin agonists) or vasopressin receptor antagonists, can modulate AQP2 expression or function indirectly by affecting the release or binding of vasopressin. These medications are used in the treatment of water balance disorders or conditions where AQP2 dysregulation is involved.

How is AQP2 regulated during vasopressin release?

Vasopressin release is triggered by changes in blood osmolality or volume. When the osmolality increases or blood volume decreases, osmoreceptors or baroreceptors in the body signal the release of vasopressin. Vasopressin then binds to its receptor in the kidney, activating the intracellular cAMP signaling pathway. This pathway leads to phosphorylation of AQP2 and its subsequent translocation to the cell membrane, increasing water reabsorption.